PERCF (Percheron Therapeutics) Retained Earnings: $-70.95 Mil (As of Dec. 2025)


What is Percheron Therapeutics Retained Earnings?

Percheron Therapeutics PERCF -0.18% Retained Earnings is $-70.95 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Percheron Therapeutics's retained earnings for the quarter that ended in Dec. 2025 was $-70.95 Mil.

Percheron Therapeutics's quarterly retained earnings increased from Dec. 2024 ($-69.83 Mil) to Jun. 2025 ($-67.49 Mil) but then declined from Jun. 2025 ($-67.49 Mil) to Dec. 2025 ($-70.95 Mil).

Percheron Therapeutics's annual retained earnings declined from Jun. 2023 ($-61.94 Mil) to Jun. 2024 ($-67.55 Mil) but then increased from Jun. 2024 ($-67.55 Mil) to Jun. 2025 ($-67.49 Mil).


Percheron Therapeutics  (OTCPK:PERCF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Percheron Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Percheron Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics Retained Earnings Chart

Percheron Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.41 -56.86 -61.94 -67.55 -67.49

Percheron Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.29 -67.55 -69.83 -67.49 -70.95

Percheron Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-70.95 Mil mean?
Percheron Therapeutics (PERCF) has a Retained Earnings of $-70.95 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Percheron Therapeutics and its competitors.
Is Percheron Therapeutics' Retained Earnings too high?
Percheron Therapeutics' current Retained Earnings is $-70.95 Mil.
How does Percheron Therapeutics' Retained Earnings compare to ZTS and UTHR?
Percheron Therapeutics' Retained Earnings of $-70.95 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Percheron Therapeutics and its competitors. Percheron Therapeutics's current Retained Earnings is $-70.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Retained Earnings of $-70.95 Mil. The current Retained Earnings is $-70.95 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Retained Earnings is $-70.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges AWY0:GermanyPER:Australia
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.